Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to determine if there is improvement in pain and other patient outcomes when using a continuous wound analgesia system after total knee replacement, compared to usual methods of pain control. Another purpose is to determine if the system makes it easier for nurses to care for these patients.
Continuous local wound infusion analgesia is a relatively new way of managing post-operative pain, whereby a local anesthetic is continuously infused into the surgical area. Some studies and users have reported decreased pain, decreased opioid use, decreased post-operative nausea and vomiting, decreased length of stay, and improved patient and caregiver satisfaction with the use of continuous local wound infusion analgesia, when compared to placebo, or usual care, in arthroplasty and other surgical interventions.
Hypotheses:
Primary:
The On-Q PainBuster (continuous wound infusion analgesia) in TKA will result in improved patient pain control, compared to usual care.
Secondary:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| S | Experimental | Patients receive the On-Q local continuous wound infusion system intra-operatively and use it for up to three days post-operatively. |
|
| C | Active Comparator | Usual care - post operative pain medications as per the knee arthroplasty care map. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| On-Q PainBuster with Bupivacaine | Device | On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pain, measured by the 11-point numerical pain rating scale | Post-operatively for three days then again at follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Post-operative nausea and vomiting | Post-operatively for three days | |
| Narcotic medications taken | Post-operatively for three days | |
| Time to first mobilization, first transfer and first 30-M walk |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Holly Meyer, MSc | Contact | 780-735-1119 | holly.meyer@capitalhealth.ca | |
| Gordon Arnett, MD | Contact | 780-455-5115 | garnett@edmontonortho.ca |
| Name | Affiliation | Role |
|---|---|---|
| Gordon Arnett, MD | Capital Health, Canada | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Alexandra Hospital | Edmonton | Alberta | Canada |
Not provided
| ID | Term |
|---|---|
| D020370 | Osteoarthritis, Knee |
| ID | Term |
|---|---|
| D010003 | Osteoarthritis |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Usual Care | Device | Usual Care |
|
| Up to three days post-operatively |
| Number of adverse events | Three days post-op (observed) then at follow-up (self-report) |
| Length of Stay | Time of surgery to discharge |
| Satisfaction (patient and caregiver) | Discharge from hospital |
| D012216 |
| Rheumatic Diseases |